Education
About Us
Working with TipRanks
Follow Us
STRATEC Biomedical (DE:SBS)
:SBS
SBS Stock Chart & Stats
Day’s Range― - ―
52-Week Range€21.00 - €48.60
Previous CloseN/A
Volume977.00
Average Volume (3M)35.99K
Market Cap
€274.12M
Enterprise Value€654.98M
Total Cash (Recent Filing)€25.02M
Total Debt (Recent Filing)€87.31M
Price to Earnings (P/E)27.4
Beta1.14
Next Earnings
Apr 29, 2025EPS EstimateN/A
Last Dividend Ex-Date
May 20, 2024Dividend Yield2.39%
Share Statistics
EPS (TTM)0.82
Shares Outstanding12,157,841
10 Day Avg. Volume42,713
30 Day Avg. Volume35,993
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.74
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€40.00Price Target Upside77.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
STRATEC Biomedical News
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
11.81%
Mutual Funds
― Other Institutional Investors
87.12% Public Companies and
Individual Investors
SBS FAQ
What was STRATEC Biomedical’s price range in the past 12 months?
STRATEC Biomedical lowest stock price was €21.00 and its highest was €48.60 in the past 12 months.
What is STRATEC Biomedical’s market cap?
STRATEC Biomedical’s market cap is €274.12M.
When is STRATEC Biomedical’s upcoming earnings report date?
STRATEC Biomedical’s upcoming earnings report date is Apr 29, 2025 which is in 18 days.
How were STRATEC Biomedical’s earnings last quarter?
STRATEC Biomedical released its earnings results on Oct 25, 2024. The company reported €0.05 earnings per share for the quarter, missing the consensus estimate of €0.38 by -€0.33.
Is STRATEC Biomedical overvalued?
According to Wall Street analysts STRATEC Biomedical’s price is currently Undervalued.
Does STRATEC Biomedical pay dividends?
STRATEC Biomedical pays a Annually dividend of €0.55 which represents an annual dividend yield of 2.39%. See more information on STRATEC Biomedical dividends here
What is STRATEC Biomedical’s EPS estimate?
STRATEC Biomedical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does STRATEC Biomedical have?
STRATEC Biomedical has 12,157,841 shares outstanding.
What happened to STRATEC Biomedical’s price movement after its last earnings report?
STRATEC Biomedical reported an EPS of €0.05 in its last earnings report, missing expectations of €0.38. Following the earnings report the stock price went down -4.097%.
Which hedge fund is a major shareholder of STRATEC Biomedical?
Currently, no hedge funds are holding shares in DE:SBS
---
STRATEC Biomedical Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€40.00 (77.38% Upside)
€40.00 (77.38% Upside)
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.10%
12-Months-Change
Fundamentals
Return on Equity
4.41%
Trailing 12-Months
Asset Growth
1.75%
Trailing 12-Months
Company Description
STRATEC Biomedical
Stratec SE, together with its subsidiaries, designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany, European Union, and internationally. It operates through three segments: Instrumentation, Diatron, and Smart Consumables. The Instrumentation segment designs and manufactures automated analyzer systems, including service parts and consumables for clinical diagnostics and biotechnology customers. The Diatron segment offers systems, system components, consumables, and tests for the low throughput hematology and clinical chemistry applications. The Smart Consumables segment develops and manufactures smart consumables in the fields of diagnostics, life sciences, and medical technologies. The company was formerly known as STRATEC Biomedical AG and changed its name to Stratec SE in December 2018. Stratec SE was founded in 1979 and is headquartered in Birkenfeld, Germany.
---
SBS Stock 12 Month Forecast
Average Price Target
€40.00
▲(77.38% Upside)
Technical Analysis
Best Analysts Covering SBS
1 Year
1 Year Success Rate
1/11 ratings generated profit
1 Year Average Return
-18.27%
reiterated a buy rating 3 months ago
Copying Michael Heider's trades and holding each position for 1 Year would result in 9.09% of your transactions generating a profit, with an average return of -18.27% per trade.
---